PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC10043419::ACT000057

MPI-C

Evidence text

Paper-level observation

Both of them had a pronounced reduction of their viabilities when treated with bioengineered OMVs ... while OMV^MPI-C had the lowest half-maximal inhibitory concentration (IC50) (Figures 2B, C).
figureConfidence: medium

Assay observation

Activity
Anticancer
Subtype
Cytotoxic
Measure
other
Comparator
=
Raw observation
lowest IC50
Normalized measurement
=0
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
MB49
Assay method
Not reported by source
Sequence
Not reported by source
Standardization
insufficient information

Source publication

Bioengineered bacterial outer membrane vesicles encapsulated Polybia–mastoparan I fusion peptide as a promising nanoplatform for bladder cancer immune-modulatory chemotherapy

Frontiers in Immunology · 2023

DOI 10.3389/fimmu.2023.1129771 PMC10043419
Parent mention

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.